68Ga-NOTA-RM26 PET/CT in Glioma Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• suspected or confirmed untreated glioma patients
• signed written consent.
Locations
Other Locations
China
Chinese Academy of Medical Science & Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Zhu
13611093752@163.com
+8613611093752
Backup
Rongxi Wang
pumch_jacobwong@163.com
+8615584172170
Time Frame
Start Date: 2022-10-01
Estimated Completion Date: 2024-05-31
Participants
Target number of participants: 30
Treatments
Experimental: 68Ga-RM26, PET/CT
Inject 68Ga-Pentixafor and then perform PET/CT scan.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital